natgillin/translations-raw huggingface dataset:
Når De begynder med at tage Odefsey, skal De holde øje med: 
Once you start taking Odefsey, look out for:
Emtricitabins biotransformation omfatter oxidation af thioldelen, hvorved der dannes 3'-sulfoxiddiastereomerer (cirka 9 % af dosen) og konjugering med glucuronsyre til at danne 2'-O-glucuronid (cirka 4 % af dosen). 
The biotransformation of emtricitabine includes oxidation of the thiol moiety to form the 3'-sulfoxide diastereomers (approximately 9% of dose) and conjugation with glucuronic acid to form 2'-O-glucuronide (approximately 4% of dose).
nedsat appetit1, øget antal triglycerider (fastende)1 
decreased appetite1, increased triglycerides (fasted)1
kvalme1,3, forhøjet pankreatisk amylase1 
nausea1, 3, increased pancreatic amylase1
Odefsey er en grå, kapselformet, filmovertrukken tablet, som er præget med ”GSI” på den ene side og tallet ”255” på den anden side. 
Odefsey is a grey, capsule-shaped, film-coated tablet debossed on one side with “GSI” and “255” on the other side.
a Uge 48-vinduet var fra dag 294 til 377 (inklusive), uge 144-vinduet var fra dag 966 til 1049 (inklusive). 
a Week 48 window was between Day 294 and 377 (inclusive); Week 144 window was between Day 966 and 1,049 (inclusive).
Eksperimenter in vitro indikerer, at rilpivirinhydrochlorid primært undergår oxidativ metabolisme medieret af CYP3A-systemet. 
In vitro experiments indicate that rilpivirine hydrochloride primarily undergoes oxidative metabolism mediated by the CYP3A system.
Hvis Odefsey stoppes uanset årsagen, skal De tale med Deres læge, før De igen begynder at tage Odefsey tabletter. 
If Odefsey is stopped for any reason, speak to your doctor before you restart taking Odefsey tablets.
Interaktioner mellem Odefsey eller de individuelle indholdsstoffer i Odefsey og mulige samtidigt administrerede lægemidler ses i tabel 1 nedenfor (stigning er angivet som ”↑”, fald som ”↓”, ingen ændring som ”↔”). 
Interactions between Odefsey or its individual component(s) and co-administered medicinal products are listed in Table 1 below (increase is indicated as “↑”, decrease as “↓” and no change as “↔”).
• rifabutin, rifampicin, rifapentin 
• rifabutin, rifampicin, rifapentine
1 Bivirkninger identificeret i kliniske studier af rilpivirin. 
1 Adverse reactions identified from rilpivirine clinical studies.
Som med andre antiretrovirale lægemidler bør resistenstest og/eller historiske resistensdata vejlede brugen af Odefsey (se pkt. 
As with other antiretroviral medicinal products, resistance testing and/or historical resistance data should guide the use of Odefsey (see section 4.4).
Renal udskillelse af intakt tenofoviralafenamid er en mindre metaboliseringsvej med < 1 % af dosen elimineret i urinen. 
Renal excretion of intact tenofovir alafenamide is a minor pathway with < 1% of the dose eliminated in urine.
Rilpivirin (en af komponenterne i Odefsey) i kombination med et baggrundsprogram evalueredes i studie TMC114HIV3015 hos 19 gravide kvinder i 2. og 3. trimester og postpartum. 
Rilpivirine (one of the components of Odefsey) in combination with a background regimen was evaluated in Study TMC114HIV3015 in 19 pregnant women during the 2nd and 3rd trimesters, and postpartum.
86 % af patienterne (62/72) var HBV-supprimerede (HBV DNA < 29 IE/ml), og 42 % (30/72) var HBeAg-positive ved baseline. 
Eighty-six percent of patients (62/72) were HBV suppressed (HBV DNA < 29 IU/mL) and 42% (30/72) were HBeAg positive at baseline.
Det er vigtigt ikke at komme til at springe en dosis af Odefsey over. 
It is important not to miss a dose of Odefsey.
Op til 30 % af emtricitabindosis kan fjernes ved hæmodialyse. 
Up to 30% of the emtricitabine dose can be removed by haemodialysis.
FTC = emtricitabin; TAF = tenofoviralafenamid; TFV = tenofovir, I/R = ikke relevant Data vises som gennemsnit (% CV). 
FTC = emtricitabine; TAF = tenofovir alafenamide; TFV = tenofovir, N/A = not applicable Data are presented as mean (%CV).
Rilpivirin-resistente stammer blev udvalgt i cellekultur startende fra vildtype hiv 1 af forskellig oprindelse og undertyper samt NNRTI-resistent hiv 1. 
Rilpivirine-resistant strains were selected in cell culture starting from wild-type HIV-1 of different origins and subtypes as well as NNRTI-resistant HIV-1.
De skal fortsætte med at være under lægens opsyn, mens De tager Odefsey. 
You must remain under the care of your doctor while taking Odefsey.
• mavesmerter eller ubehag 
• stomach pain or discomfort
Odefsey bruges til voksne og unge i alderen 12 år og ældre, der vejer mindst 35 kg. 
Odefsey is used in adults and adolescents aged 12 years and older, who weigh at least 35 kg.
Behandlingsresultaterne i studierne GS-US-366-1216 og GS-US-366-1160 vises i tabel 5. 
Treatment outcomes of Studies GS-US-366-1216 and GS-US-366-1160 are presented in Table 5.
Resistenstest og/eller historiske resistensdata bør vejlede brugen af Odefsey (se pkt. 
Resistance testing and/or historical resistance data should guide the use of Odefsey (see section 5.1).
De samlede behandlingsresultater efter 48 og 144 uger vises i tabel 3. 
Pooled treatment outcomes at 48 and 144 weeks are shown in Table 3.
Ved starten af behandlingen med E/C/F/TAF havde 72 patienter været hiv-supprimerede (hiv-1 RNA < 50 kopier/ml) i mindst 6 måneder med eller uden supprimering af HBV DNA, og de havde kompenseret leverfunktion. 
At the start of treatment with E/C/F/TAF, the 72 patients had been HIV suppressed (HIV-1 RNA < 50 copies/mL) for at least 6 months with or without suppression of HBV DNA and had compensated liver function.
Andelen af patienter med hiv 1-rna < 50 kopier/ml ved uge 48 (TLOVR) var 72,2 % (26/36). 
The proportion of patients with HIV-1 RNA < 50 copies/mL at Week 48 (TLOVR) was 72.2% (26/36).
Patienterne bør informeres om, at der er rapporteret om træthed, svimmelhed og søvnighed under behandling med indholdsstofferne i Odefsey (se pkt. 
Patients should be informed that fatigue, dizziness and somnolence have been reported during treatment with the components of Odefsey (see section 4.8).
Dosisanbefalingerne gælder for den anbefalede dosis af rilpivirin på 25 mg en gang dagligt. 
The dosing recommendation is applicable to the recommended dose of rilpivirine of 25 mg once daily.
Hos patienter med svært nedsat nyrefunktion eller nyresygdom i sidste stadie kan plasmakoncentrationer være forhøjede på grund af ændret absorption, distribution og/eller metabolisme af lægemidler som følge af renal dysfunktion. 
In patients with severe renal impairment or end-stage renal disease, plasma concentrations may be increased due to alteration of drug absorption, distribution and/or metabolism secondary to renal dysfunction.
Risikoen for stigninger i plasmakoncentrationerne af dabigatran kan ikke udelukkes (hæmning af intestinal P-gp). 
A risk for increases in dabigatran plasma concentrations cannot be excluded (inhibition of intestinal P-gp).
Titandioxid (E171) Jernoxid, sort (E172) 
Titanium dioxide (E171) Iron oxide black (E172)
Tegn på osteonekrose er: stivhed i led smerter i led (især i hofter, knæ og skuldre) bevægelsesbesvær 
Signs of osteonecrosis are: joint stiffness joint aches and pains (especially of the hip, knee and shoulder) difficulty with movement
Odefsey skal anvendes med forsigtighed hos patienter med moderat nedsat leverfunktion. 
Odefsey should be used with caution in patients with moderate hepatic impairment.
I et studie, der sammenlignede 8 patienter med let nedsat leverfunktion (Child-Pugh-klasse A) med 8 matchede kontroller og 8 patienter med moderat nedsat leverfunktion (Child-Pugh-klasse B) med 8 matchede kontroller, var flerdosis eksponering for rilpivirin 47 % højere hos patienter med let nedsat leverfunktion og 5 % højere hos patienter med moderat nedsat leverfunktion. 
In a study comparing 8 patients with mild hepatic impairment (Child-Pugh Class A) to 8 matched controls and 8 patients with moderate hepatic impairment (Child-Pugh Class B) to 8 matched controls, the multiple dose exposure of rilpivirine was 47% higher in patients with mild hepatic impairment and 5% higher in patients with moderate hepatic impairment.
På baggrund af lægemiddelinteraktionsstudier udført med Odefseys indholdsstoffer forventes der ingen klinisk signifikante interaktioner, når Odefsey kombineres med følgende lægemidler: buprenorphin, naloxon og norbuprenorphin. 
Studies conducted with other medicinal products Based on drug-drug interaction studies conducted with the components of Odefsey, no clinically significant interactions are expected when Odefsey is combined with the following medicinal products: buprenorphine, naloxone and norbuprenorphine.
I dette studie svarede sikkerhedsprofilen for unge patienter til den for voksne (se pkt. 
In this study, the safety profile in adolescent patients was similar to that in adults (see section 5.1).
I/R 10,0 (19,6) 
N/A 10.0 (19.6)
Hold ikke op med at tage Odefsey Hold ikke op med at tage Odefsey uden at tale med Deres læge. 
Do not stop taking Odefsey Do not stop taking Odefsey without talking to your doctor.
Odefsey fås i tabletbeholdere med 30 tabletter samt i pakninger med 3 tabletbeholdere hver med 30 tabletter. 
Odefsey comes in bottles of 30 tablets and in packs made up of 3 bottles, each containing 30 tablets.
Ved supraterapeutiske doser (75 mg en gang om dagen og 300 mg en gang om dagen) er rilpivirin blevet forbundet med forlængelse af QTc-intervallet i elektrokardiogrammet (EKG) (se pkt. 
At supratherapeutic doses (75 mg once daily and 300 mg once daily), rilpivirine has been associated with prolongation of the QTc interval of the electrocardiogram (ECG) (see sections 4.5 and 4.9).
Filmovertræk: Macrogol, polyvinylalkohol, talcum, titandioxid (E171), jernoxid, sort (E172). 
Film-coating: Macrogol, polyvinyl alcohol, talc, titanium dioxide (E171), iron oxide black (E172).
Patienter, som får Odefsey, har fortsat risiko for opportunistiske infektioner eller andre hiv-relaterede komplikationer, og bør derfor følges nøje af læger med erfaring i behandlingen af patienter med hiv-associerede sygdomme. 
Patients receiving Odefsey may continue to develop opportunistic infections and other complications of HIV infection, and therefore should remain under close clinical observation by physicians experienced in the treatment of patients with HIV associated diseases.
Unge i alderen 12 år og ældre, som vejer mindst 35 kg: en tablet om dagen sammen med mad Tabletten må ikke tygges, knuses eller deles. 
Adolescents 12 years of age and older, who weigh at least 35 kg: one tablet each day with food Do not chew, crush or split the tablet.
Der bør kun anvendes H2receptorantagonister, som kan doseres en gang dagligt. 
Only H2-receptor antagonists that can be dosed once daily should be used.
a n = 24 unge (GS-US-292-0106), n = 19 voksne (GS-US-292-0102). 
a n = 24 adolescents (GS-US-292-0106); n = 19 adults (GS-US-292-0102).
Sent forekommende neurologiske forstyrrelser er blevet rapporteret i sjældne tilfælde (hypertoni, kramper, unormal adfærd). 
Late onset neurological disorders have been reported rarely (hypertonia, convulsion, abnormal behaviour).
Brug af anden medicin sammen med Odefsey Fortæl altid lægen eller apotekspersonalet, hvis De tager anden medicin eller har gjort det for nylig. 
Other medicines and Odefsey Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Børn og unge Denne medicin må ikke gives til børn i alderen 11 år eller derunder eller børn, som vejer under 
Children and adolescents Do not give this medicine to children aged 11 years or under, or weighing less than 35 kg.
K65R- og også K70E-substitution resulterer i nedsat følsomhed for abacavir, didanosin, lamivudin, emtricitabin og tenofovir, men de bevarer følsomhed for zidovudin. 
The K65R and also the K70E substitution result in reduced susceptibility to abacavir, didanosine, lamivudine, emtricitabine, and tenofovir, but retain sensitivity to zidovudine.
Rilpivirinhydrochlorid metaboliseres og elimineres primært i leveren. 
Rilpivirine hydrochloride is primarily metabolised and eliminated by the liver.
Interaktion er ikke blevet undersøgt med nogen af Odefseys indholdsstoffer. 
Interaction not studied with any of the components of Odefsey.
Rilpivirin er en diarylpyrimidin NNRTI af hiv 1. 
Rilpivirine is a diarylpyrimidine NNRTI of HIV-1.
For en sikkerheds skyld bør anvendelse af Odefsey under graviditet undgås. 
As a precautionary measure, it is preferable to avoid the use of Odefsey during pregnancy.
Odefsey frarådes til patienter med en estimeret CrCl ≥ 15 ml/min og < 30 ml/min, eller < 15 ml/min, som ikke er i kronisk hæmodialyse, da Odefseys sikkerhed hos disse populationer ikke er klarlagt. 
Odefsey should be avoided in patients with estimated CrCl ≥ 15 mL/min and < 30 mL/min, or < 15 mL/min who are not on chronic haemodialysis, as the safety of Odefsey has not been established in these populations.
Der skal tages hensyn til disse resultater for alle børn, der er blevet eksponeret for nukleoside/nukleotide analoger in utero, og som præsenterer svære kliniske fund af ukendt ætiologi, især neurologiske fund. 
These findings should be considered for any child exposed in utero to nucleos(t)ide analogues, who present with severe clinical findings of unknown etiology, particularly neurologic findings.
Blandt disse 12 hiv 1-isolater var de mutationer, der opstod, M184V/I (n = 11) og K65R/N (n = 2) i RT og T66T/A/I/V (n = 2), E92Q (n = 4), Q148Q/R (n = 1) og N155H (n = 2) i integrase. 
Among these 12 HIV-1 isolates, the mutations that emerged were M184V/I (n = 11) and K65R/N (n = 2) in RT and T66T/A/I/V (n = 2), E92Q (n = 4), Q148Q/R (n = 1), and N155H (n = 2) in integrase.
Patienter med hiv-infektion, som samtidig er inficerede med HBV, og som ophører med Odefsey, bør monitoreres tæt med opfølgning både klinisk og i laboratoriet i flere måneder eller længere efter ophør af behandlingen. 
Patients co-infected with HIV and HBV who discontinue Odefsey should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment.
H2-antagonister må ikke tages to gange om dagen. 
H2-antagonists should not be taken twice a day.
I/R 10,6 (28,5) 
N/A 10.6 (28.5)
Desuden hæmmede emtricitabin ikke uridine-5'-diphosphoglucuronyltransferase (UGT), det enzym, der er ansvarligt for glucuronidation. 
Also, emtricitabine did not inhibit uridine-5'-diphosphoglucuronyl transferase (UGT), the enzyme responsible for glucuronidation.
Hos patienter med allerede eksisterende leverdysfunktion, herunder kronisk aktiv hepatitis, er der en forhøjet forekomst af unormal leverfunktion under antiretroviral kombinationsbehandling (CART, combination antiretroviral therapy), og disse patienter bør monitoreres i henhold til standardprocedurer. 
Patients with pre-existing liver dysfunction, including chronic active hepatitis, have an increased frequency of liver function abnormalities during combination antiretroviral therapy (CART) and should be monitored according to standard practice.
Efter administration af tenofoviralafenamid viste plasma [14C]-radioaktivitet en tidsafhængig profil med tenofoviralafenamid som det hyppigste stof i de første par timer og urinsyre i den resterende periode. 
Following administration of tenofovir alafenamide, plasma [14C] -radioactivity showed a time-dependent profile, with tenofovir alafenamide as the most abundant species in the initial few hours and uric acid in the remaining period.
artralgi3 
arthralgia3
GLUKOKORTIKOIDER Dexamethason (systemisk, med undtagelse af anvendelse af en enkelt dosis) 
GLUCOCORTICOIDS Dexamethasone (systemic, except for single dose use)
Emtricitabins binding in vitro til humane plasmaproteiner var < 4 % og uafhængig af koncentrationen i intervallet 0,02-200 µg/ml. 
In vitro binding of emtricitabine to human plasma proteins was < 4% and independent of concentration over the range of 0.02-200 µg/mL.
52 % af hiv 1-isolater med nyopstået resistent i rilpivirin-armen udviklede samtidige NNRTI- og NRTI-mutationer, oftest E138K og M184V. 
Fifty-two percent of HIV-1 isolates with emergent resistance in the rilpivirine arm developed concomitant NNRTI and NRTI mutations, most frequently E138K and M184V.
Sofosbuvirmetabolit GS-331007: 
Sofosbuvir metabolite GS-331007:
e f.eks. manglende opfølgning, manglende compliance, samtykke trukket tilbage. 
e e.g., lost to follow up, non-compliance, withdrew consent.
Grå, kapselformede, filmovertrukne tabletter, der måler 15 mm x 7 mm, præget med ”GSI” på den ene side af tabletten og med ”255” på den anden side af tabletten. 
Grey, capsule-shaped, film-coated tablets, of dimensions 15 mm x 7 mm, debossed with “GSI” on one side of the tablet and “255” on the other side of the tablet.
Der er ikke blevet identificeret klinisk relevante farmakokinetiske forskelle på grund af alder, køn eller etnicitet for emtricitabin, rilpivirin eller tenofoviralafenamid. 
No clinically relevant pharmacokinetic differences due to age, gender or ethnicity have been identified for emtricitabine, rilpivirine or tenofovir alafenamide.
Odefseys sikkerhed og virkning hos patienter med signifikant underliggende leversygdom er ikke klarlagt. 
The safety and efficacy of Odefsey in patients with significant underlying liver disorders have not been established.
En minimal infiltration af histiocytter var til stede i øjet på hunde ved eksponeringer over for hhv. tenofoviralafenamid og tenofovir, der var ca. 4 og 17 gange større, end hvad der forventes efter administration af Odefsey. 
A minimal infiltration of histiocytes was present in the eye in dogs at tenofovir alafenamide and tenofovir exposures of approximately 4 and 17 times greater, respectively, than those expected after administration of Odefsey.
Odefsey 200 mg/25 mg/25 mg filmovertrukne tabletter 
Odefsey 200 mg/25 mg/25 mg film-coated tablets
H2-antagonister (famotidin, cimetidin, nizatidin eller ranitidin) Disse lægemidler kan mindske mængden af rilpivirin (et indholdsstof i Odefsey) i Deres blod. 
H2-antagonists (famotidine, cimetidine, nizatidine or ranitidine) These medicines can decrease the amount of rilpivirine (a component of Odefsey) in your blood.
Patienter med en virusbelastning ved baseline > 100.000 hiv 1-rna-kopier/ml, som fik virologisk svigt, havde en højere forekomst af resistens over for NNRTI-klassen som følge af behandlingen. 
Patients with a baseline viral load > 100,000 HIV-1 RNA copies/mL who experienced virologic failure exhibited a higher rate of treatment-emergent resistance to the NNRTI class.
Brug ikke lægemidlet efter den udløbsdato, der står på pakningen og tabletbeholderen efter Exp. Udløbsdatoen er den sidste dag i den nævnte måned. 
Do not use this medicine after the expiry date which is stated on the carton and bottle after {EXP}.
c n = 539 (TAF) eller 841 (TFV) voksne (GS-US-292-0111 og GS-US-292-0104, populationsfarmakokinetisk analyse). 
c n = 539 (TAF) or 841 (TFV) adults (GS-US-292-0111 and GS-US-292-0104, population PK analysis).
Anvendelsen af Odefsey til børn i alderen 11 år eller derunder, eller som vejer under 35 kg, er endnu ikke undersøgt. 
The use of Odefsey in children aged 11 years or under or weighing less than 35 kg has not yet been studied.
De mutationer associeret med NRTI-resistens, der udviklede sig i 3 eller flere patientisolater, var: K65R, K70E, M184V/I og K219E. 
The mutations associated with NRTI resistance that developed in 3 or more patient isolates were: K65R, K70E, M184V/I and K219E.
Rilpivirin udviste aktivitet mod laboratoriestammer af vildtype hiv 1 i en stærkt inficeret T-cellelinje med en median EC50-værdi for hiv 1/IIIB på 0,73 nM (0,27 ng/ml). 
Rilpivirine exhibited activity against laboratory strains of wild-type HIV-1 in an acutely infected T-cell line with a median EC50 value for HIV-1/IIIB of 0.73 nM (0.27 ng/mL).
Dosisjusteringer er ikke nødvendige. 
No dose adjustments are required.
Det er muligt, at patienter i fremtiden, der har brugt Odefsey gennem længere tid, kan få nyreproblemer. 
It is possible that in the future, long-term users of Odefsey may get kidney problems.
• Lægemidler mod mavesår, halsbrand og sure opstød som f.eks.: 
• Medicines for stomach ulcers, heartburn or acid reflux such as:
Dyrestudier tyder ikke på skadelige virkninger af emtricitabin, rilpivirinhydrochlorid eller tenofoviralafenamid på fertiliteten (se pkt. 
Animal studies do not indicate harmful effects of emtricitabine, rilpivirine hydrochloride or tenofovir alafenamide on fertility (see section 5.3).
Den mediane stigning fra baseline for disse parametre var større hos patienter, der fik FTC + TAF, sammenlignet med patienter, der fik FTC + TDF (p < 0,001 for forskellen mellem behandlingsgrupperne angående fasteværdier for total-kolesterol, direkte LDL- og HDL-kolesterol samt triglycerider). 
The median increase from baseline for these parameters was greater in patients receiving FTC + TAF compared with patients receiving FTC + TDF (p < 0.001 for the difference between treatment groups for fasting total cholesterol, direct LDL- and HDL-cholesterol, and triglycerides).
Lægemidler, der inducerer eller hæmmer CYP3A, kan således påvirke rilpivirin-clearance (se pkt. 
Medicinal products that induce or inhibit CYP3A may thus affect the clearance of rilpivirine (see section 5.2).
Behandlingsnaive voksne i studierne GS-US-292-0104 og GS-US-292-0111b 
Treatment-naïve adults in Studies GS-US-292-0104 and GS-US-292-0111b
Nukleosid/nukleotid-analoger kan påvirke mitokondriefunktionen i varierende grad; dette er mest udtalt ved stavudin, didanosin og zidovudin. 
Nucleos(t)ide analogues may impact mitochondrial function to a variable degree, which is most pronounced with stavudine, didanosine and zidovudine.
svære hudreaktioner med systemiske symptomer4, angioødem5,6, pruritus3, urticaria6 Knogler, led, muskler og bindevæv Ikke almindelig: 
severe skin reactions with systemic symptoms4, angioedema5, 6, pruritus3, urticaria6 Musculoskeletal and connective tissue disorders Uncommon:
I studierne GS-US-292-0104 og GS-US-292-0111 var den virologiske succesrate den samme i alle patientundergruppe (alder, køn, race, hiv 1-rna ved baseline eller CD4+ celletal ved baseline). 
In Studies GS-US-292-0104 and GS-US-292-0111, the rate of virologic success was similar across patient subgroups (age, gender, race, baseline HIV-1 RNA, or baseline CD4+ cell count).
• forhøjede niveauer af leverenzymer i blodet 
• increased levels of liver enzymes in the blood
Forekomsten af virologisk svigt hos patienter behandlet med emtricitabin/tenofovirdisoproxilfumarat + rilpivirin var i uge 48 og uge 96 henholdsvis 9,5 % og 11,5 %, og 4,2 % og 5,1 % i armen med emtricitabin/tenofovirdisoproxilfumarat + efavirenz. 
The virologic failure rate in patients treated with emtricitabine/tenofovir disoproxil fumarate + rilpivirine at Week 48 and Week 96 was 9.5% and 11.5% respectively, and 4.2% and 5.1% in the emtricitabine/tenofovir disoproxil fumarate + efavirenz arm.
depression1, unormale drømme1,3, søvnforstyrrelser1, forsænket stemningsleje1 
depression1, abnormal dreams1, 3, sleep disorders1, depressed mood1
På dage med hæmodialyse, skal Odefsey administreres efter fuldført hæmodialysebehandling. 
On days of haemodialysis, Odefsey should be administered after completion of haemodialysis treatment.
Rilpivirin er en hæmmer af transportøren MATE-2K in vitro med en IC50 på < 2,7 nM. 
Rilpivirine is an in vitro inhibitor of the transporter MATE-2K with an IC50 of < 2.7 nM.
Tenofovirs binding in vitro til humane plasmaproteiner var < 0,7 % og er uafhængig af koncentrationen i intervallet 0,01-25 µg/ml. 
In vitro binding of tenofovir to human plasma proteins is < 0.7% and is independent of concentration over the range of 0.01-25 µg/mL.
Den farmakokinetiske eksponering for rilpivirin hos patienter med samtidig infektion, var sammenlignelig med den hos patienter uden samtidig infektion. 
The pharmacokinetic exposure of rilpivirine in co-infected patients was comparable to that in patients without co-infection.